BIOCUBE, INC.

7320 North Dreamy Draw Drive
Suite 120
Phoenix, AZ 85020

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

BIOCUBE, INC.

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 7320 North Dreamy Draw Drive
Address 2: Suite 120
Address 3: Phoenix, AZ 85020
Phone: 646-450-6194
Email: info@biocubeinc.com
Website(s): http://www.biocubeinc.com

IR Contact
Address 1: _____
Address 2: _____
Address 3: _____
Phone: _____
Email: _____
Website(s): _____

3) Security Information

Trading Symbol: BICB

Exact title and class of securities outstanding: Common
CUSIP: 018697102
Par or Stated Value: .001
Total shares authorized: 300,000,000 as of: 12/2/16
Total shares outstanding: 64,342,700 as of: 12/2/16

Additional class of securities (if necessary):
Trading Symbol: BICB
Exact title and class of securities outstanding: Series A Preferred
CUSIP: N/A
Par or Stated Value: .001
Total shares authorized: 21,000 as of: December 2, 2016
Total shares outstanding: 21,000 as of: December 2, 2016

The sum total of Series A Preferred Shares have voting rights always equal to exactly 50.1% of all voting rights.

Transfer Agent
Name: Action Stock Transfer Corporation
Address 1: 2469 E. Fort Union Blvd
Address 2: Suite 214
Address 3: Salt Lake City, UT 84121
Phone: 801-274-1088
Is the Transfer Agent registered under the Exchange Act?* Yes: ☒ No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

No

B. Any jurisdictions where the offering was registered or qualified;

No

C. The number of shares offered;

None

D. The number of shares sold;

None

E. The price at which the shares were offered, and the amount actually paid to the issuer;

N/A

F. The trading status of the shares; and

N/A

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

N/A

5) Financial Statements

The financial statements are incorporated by reference- Financial Statements 01-31-16

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

BioCube, Inc. (the "Company") through its partially-owned subsidiary IUT Technologies Inc. ("IUT") plans to market and distribute in North America certain devices for the detection of THC and marijuana on a user's breath and other devices based upon trace gas analyzers for industrial- and environmental monitoring and for solutions in the homeland security and building protection. The Company previously had operated several other marketing and distribution businesses for electrical surge protection devices; aerosol based decontamination systems; and batteries utilizing a proprietary and patented process. These businesses were terminated as each new venture was commenced.

B. Date and State (or Jurisdiction) of Incorporation:

Delaware- 7/30/2007

C. the issuer's primary and secondary SIC Codes;

3822

D. the issuer's fiscal year end date;

1/31

E. principal products or services, and their markets;

N/A

7) Describe the Issuer's Facilities

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Paul Lisak-CEO
Jan Chason-Director

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Paul Lisak — 4,000,000 Common (6.22%)
7320 North Dreamy Draw Drive
Suite 120
Phoenix, AZ 85020

Jan Chason — 2,000,000 Common (3.11%)
7320 North Dreamy Draw Drive
Suite 120
Phoenix, AZ 85020

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Name: William Eilers
Firm: Eilers Law Group,P.A.
Address 1: 1000 5th St
Address 2: Suite 200-P2
Address 3: Miami Beach, FL 33139
Phone: 786-273-9152
Email: wreilers@eilerslawgroup.com

Accountant or Auditor
Name:
Firm:
Address 2:
Address 3:
Phone:
Email:

Investor Relations Consultant
Name: N/A

Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.
Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Paul Lisak certify that:

1. I have reviewed this annual disclosure statement of BioCube, Inc;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

12/2/2016
/s/ PAUL LISAK
CEO